

Corp. Office : 1st to 4th Floor, SM House, 11, Sahakar Road, Vile Parle (East), Mumbai - 400 057.
Tel. : (91-22) 6726 1000 Fax : (91-22) 6726 1068 E-mail : info@guficbio.com, CIN No. L24100MH1984PLC033519

21/LG/SE/MARCH/2021/GBSL

March 17, 2021

To,
Listing Department,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001
Security Code :509079

To,
Listing Department,
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
Security Code : GUFICBIO

Sub: Announcement under Regulation 30 of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015: Sanction of the Scheme of Merger by Absorption of Gufic Lifesciences Private Limited with Gufic Biosciences Limited and their respective shareholders by the NCLT, Mumbai Bench

This is in furtherance to our letter dated January 04, 2021 intimating the Exchanges about the sanction of the Scheme of Merger by Absorption of Gufic Lifesciences Private Limited (“Transferor Company”) with Gufic Biosciences Limited (“Transferee Company”) and their respective shareholders and creditors (“Scheme”) by the Hon’ble National Company Law Tribunal, Ahmedabad bench vide its order dated December 31, 2020, subject to the final order in the proceedings of the Transferee Company before the Hon’ble National Company Law Tribunal, Mumbai bench.

We are pleased to inform you that the National Company Law Tribunal, Mumbai bench has by its order pronounced in the open court held through Video Conferencing on March 11, 2021 sanctioned the said Scheme and the certified true copy of the said order is awaited. The status of the said hearing has been updated as “Allowed” on the website of the National Company Law Tribunal, today. This was the last pending regulatory permission for implementing the said Scheme. As mentioned in the Scheme, the appointed date of the Scheme is January 01, 2019 and upon receipt of the certified copy of the order, we shall initiate the process to file the same with the Registrar of Companies and accordingly, implement the Scheme.

On the merger being effective, the Company will own the state of the art EU GMP approved Lyophilized Injectable facility situated at Navsari that caters to regulated and semi regulated markets. Taking into consideration the financials of the Transferor Company for the period ending December 31, 2020, the consolidated unaudited figures of the Company and the Transferor Company is as follows:

Total Revenue from Operations: Rs. 355.80 crores
Net Profit Before Tax: Rs. 40.60 crores



Corp. Office : 1st to 4th Floor, SM House, 11, Sahakar Road, Vile Parle (East), Mumbai - 400 057.
Tel : (91-22) 6726 1000 Fax : (91-22) 6726 1068 E-mail : info@guficbio.com, CIN No. L24100MH1984PLC033519

Further, with a rich pipeline of complex and high value lyophilised injectable products targeted at India and international markets, the Company will derive significant synergies from this merger.

The above is for your information and record. This may be treated as disclosure under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

Yours Faithfully,

For Gufic Biosciences Limited



Ami N. Shah

Company Secretary & Compliance Officer

Mem No. A39579

